Ultragenyx Pharmaceutical | RARE - Ordinary Share Capital


Ultragenyx Pharmaceutical reported $98.3M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Immunic USD 120.38M 21.73M Dec/2025
Insmed USD 218.28M 1.76M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Kyowa Hakko Kirin JPY 523.59M 99K Jun/2026
MacroGenics USD 63.56M 241K Mar/2026
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.55M 50K Jun/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026